Biotech Values

[DewDiligence]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program is in phase-3 or beyond and is non-partnered; AND
b) Company does not have the financial resources to develop and market the product.

Edits: Removed Cougar’s Abiraterone (co acquired by JNJ); removed
CHTP’s Droxidopa (failed in phase-3); removed DYAX’s DX-88 for HAE
(co plans to market this indication in-house); removed RPRX’s Proellex
(program effectively dead); updated status of SVNT’s Krystexxa, PLX’s
prGCD, and Pharmings’s Rhucin; added MNKD’s Afresa. Changed formatting;
expanded inclusion criteria to programs with inadequate funding for
commercialization (as well as inadequate funding for clinical development).

 
 Company  Product    Phase/status  Indication (notes) 
 =======  =======    ============  ================== 
 ARNA     Lorcaserin      3        Obesity   
 BPAX     Libigel         3        Female Sexual Desire Disorder 
 GNVC     TNFerade        3        Non-met pancreatic cancer   
 JAV      Dyloject        3        Post-op pain (approved in UK) 
 JAV      Ketamine        3        Acute pain 
 OREX     Contrave        3        Obesity   
 OXGN     Zybrestat       3        Anaplastic thyroid cancer      
 MNKD     Afresa       pre-BLA     Type-1/2 diabetes 
 Pharming Rhucin       pre-BLA     HAE (rejected and resubmitted in EU)  
 PLX      prGCD        pre-BLA     Gaucher's disease 
 SVNT     Krystexxa    CRL rec’d   Gout (CMC section of BLA has problems)

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.